Brunhilde Felding-Habermann
Overview
Explore the profile of Brunhilde Felding-Habermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kularatne S, Deshmukh V, Ma J, Tardif V, Lim R, Pugh H, et al.
Angew Chem Int Ed Engl
. 2014 Sep;
53(44):11863-7.
PMID: 25213874
A chemically defined anti-CXCR4-auristatin antibody-drug conjugate (ADC) was synthesized that selectively eliminates tumor cells overexpressing the CXCR4 receptor. The unnatural amino acid p-acetylphenylalanine (pAcF) was site-specifically incorporated into an anti-CXCR4...
2.
Santidrian A, Matsuno-Yagi A, Ritland M, Seo B, LeBoeuf S, Gay L, et al.
J Clin Invest
. 2013 Feb;
123(3):1068-81.
PMID: 23426180
Despite advances in clinical therapy, metastasis remains the leading cause of death in breast cancer patients. Mutations in mitochondrial DNA, including those affecting complex I and oxidative phosphorylation, are found...
3.
Axup J, Bajjuri K, Ritland M, Hutchins B, Kim C, Kazane S, et al.
Proc Natl Acad Sci U S A
. 2012 Sep;
109(40):16101-6.
PMID: 22988081
Antibody-drug conjugates (ADCs) allow selective targeting of cytotoxic drugs to cancer cells presenting tumor-associated surface markers, thereby minimizing systemic toxicity. Traditionally, the drug is conjugated nonselectively to cysteine or lysine...
4.
Gay L, Felding-Habermann B
Cancer Cell
. 2011 Nov;
20(5):553-4.
PMID: 22094248
Metastasis of epithelial tumors critically depends on acquisition of a disseminating phenotype that allows tumor cells to colonize distant organs. In this issue of Cancer Cell, Labelle et al. demonstrate...
5.
Goswami R, Bajjuri K, Forsyth J, Das S, Hassenpflug W, Huang Z, et al.
Bioconjug Chem
. 2011 Jul;
22(8):1535-44.
PMID: 21774545
Integrins αvβ3 and αvβ6 are highly expressed on tumor cells and/or by the tumor vasculature of many human cancers, and represent promising targets for anticancer therapy. Novel chemically programmed antibodies...
6.
Hutchins B, Kazane S, Staflin K, Forsyth J, Felding-Habermann B, Smider V, et al.
Chem Biol
. 2011 Mar;
18(3):299-303.
PMID: 21439474
We report a strategy for the generation of heterodimeric protein conjugates using an unnatural amino acid with orthogonal reactivity. This paper addresses the challenges of site-specificity and homogeneity with respect...
7.
Gay L, Felding-Habermann B
Nat Rev Cancer
. 2011 Jan;
11(2):123-34.
PMID: 21258396
Extensive experimental evidence shows that platelets support tumour metastasis. The activation of platelets and the coagulation system have a crucial role in the progression of cancer. Within the circulatory system,...
8.
Hutchins B, Kazane S, Staflin K, Forsyth J, Felding-Habermann B, Schultz P, et al.
J Mol Biol
. 2011 Jan;
406(4):595-603.
PMID: 21237172
Immunoconjugates and multispecific antibodies are rapidly emerging as highly potent experimental therapeutics against cancer. We have developed a method to incorporate an unnatural amino acid, p-acetylphenylalanine (pAcPhe) into an antibody...
9.
Lorger M, Felding-Habermann B
Am J Pathol
. 2010 Apr;
176(6):2958-71.
PMID: 20382702
Brain metastases are difficult to treat and mostly develop late during progressive metastatic disease. Patients at risk would benefit from the development of prevention and improved treatments. This requires knowledge...
10.
Staflin K, Krueger J, Hachmann J, Forsyth J, Lorger M, Steiniger S, et al.
Clin Exp Metastasis
. 2010 Mar;
27(4):217-31.
PMID: 20225083
Advanced metastatic disease is difficult to manage and specific therapeutic targets are rare. We showed earlier that metastatic breast cancer cells use the activated conformer of adhesion receptor integrin alphavbeta3...